K V Pharmaceutical Co (NASDAQOTH:KVPHQ)

Lets hope it will run back to $6 soon...

It will not be around for longer than 2012

Lttle chinese mix>

Why this stock is not presente in Google Finance

Sell

Too much uncertainty right now, still coming under heavy fire, significant price drop on Makena will hurt margins going forward, stock still up quite a bit since FDA approval (even with recent plunge). Too risky for my blood.

No doubt ,KV has the exclusive rights to Makena which has FDA approval and Doctors will turn to Makena as their sole recomendation for women who have lost pre-term babies, and are now pregnant...

its just matter of time

Alright, I''ve rode this up and then red thumbed it and rode it down. It's priced to be a good choice for the long run again.

I strongly believe that KV is taking right steps toward the pricing. Makena is a very important drug and will be having a huge user base in coming months. Makena deserves a primium pricing over compound pharmacies drug, and I guess no body has a doubt against it considering the safety and underneath cose involved plus a responsible company behind it. To me, it seems like some of the articles/disucssion is unnecessary and very negatively approached.

I am long on KV.

Rode it up on the FDA approval, getting back in after the lower-than-hoped-for price news. I think it will still move up.

Makena has amazing potential- On the basis of the New England Jounal of Medicine Article 2003 the drug truly does benefit in preterm labor. Demand is going to be hard to fill. OBs use this drug on a regular basis compounded from pharmacies. It is going to make it a lot easier to dispense to patients. In the end we will help prevent much of the sequela from preterm labor if taken in time. It is truly a breakthrough...

New drug with hot chart a little competition

This one is going to fly. With their recently approved Makena, a medication labelled to treat pre-term birth, this company is definitely going places. They currently hold FDA approval for the only medication currently available that is specifically labelled to prevent pre-term births. The market for this medication is huge, and KV-A won't have any competitors for quite some time. The next year will be very interesting as KV begins marketing and selling Makena this March 2011.

In addition to all of this, KV-A also has other projects and medications in their pipeline to strengthen the fundamentals even more. This one is a winner, for sure. The next year will probably be turbulent, but a strong upward trend will ultimately prevail.

These guys have a blockbuster on their hands (Makena)....why? ppl have to realize two things: Makena is a huge profit margin drug ($1500 per injection) and it will be covered by all healthcare plans (see below).

While the number of premature births (and thus the market for Makena) may not be as large as for typical blockbuster drugs, the cost to the healthcare system from premature births is disproportionately high. This is what allows Makena to get away with such high margins since $1500 per injection to prevent a premature birth is still way cheaper than the costs of long-term care for premature babies in hospitals. This is money in the bank for K V.

just in the United States, about 12.8 percent of babies (more than half a million a year) are born prematurely

Kv-A has recently gotten their new drug Makena approved by the FDA which means they now have a "monopoly" on the first drug capable of reducing the risk of premature birth. Premature birth cost the US alone over 26 billion dollars each year... The road to recovery for Kv pharmaceutical looks much brighter and possibly holds an even greater financial future for Kv-a in the coming years.

New Management, New Drug Approval, FDA approval of production processes

2/14/2011 Happy kV-a day!